A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Trial Profile

A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Asunercept (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors CANbridge Life Sciences
  • Most Recent Events

    • 26 Sep 2016 According to a CANbridge Life Sciences media release, the first patient was dosed in the this study. Company expects to report Phase I safety data after mid-2017.
    • 08 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 26 Jul 2016 According to a CANbridge Life Sciences media release, the Taiwan Food and Drug Administration (TFDA) has approved the Investigational New Drug (IND) application for a Phase I/II clinical study of CAN-008, plus temozolomide (TMZ), during and after radiation therapy, in patients with newly-diagnosed glioblastoma multiforme (GBM).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top